Abstract
Introduction: The goal of any physician who cares about dialysis patients is to increase their quality of life. Many studies have shown that residual renal function (RRF) in dialysis patients, especially those undergoing peritoneal dialysis (PD), is an important prognostic factor for mortality. Objectives: In the present study, we aimed to investigate the effect of N-acetylcysteine (NAC) as an antioxidant on increasing RRF in chronic hemodialysis (HD) patients. Patients and Methods: Ninety-eight chronic HD patients who have urinary output greater than 100 cc in 24 hours participated in this study and were divided into two groups of treatment and control (49 patients each). Subsequently, the oral NAC treatment group received 600 mg tablets twice a day before meals. The control group received placebo tablets again twice a day before meals. The duration of the study was 4 weeks. Results: The RRF significantly improved in the treatment group during the study period, but no significant changes were observed in the control group. Residual glomerular filtration rate (GFR) rose from 1.7±0.73 to 2.7±1.1 mL/min/1.73 m2 (P<0.0001) in the treatment group, while in the control group, there was a slight increase from 2.1±0.94 to 2.2±1.19 mL/min/1.73 m2 (P=0.26). Additionally, the average daily volume of urine in the treatment group increased from 594±436 to 953±540 mL/24 h (P<0.0001) in the treatment group and from 809±573 to 771±552 mL/24 h (P=0.11) in the control group. Finally, the calculation of residual renal Kt/V per week showed an increase from 0.21±0.06 to 0.31±0.08 (P<0.0001) in the treatment group and a decrease from 0.23±0.08 to 0.22±0.08 (P=0.22) in the control group. Conclusion: Our study showed that a 4-week NAC treatment improves RRF in chronic HD patients.
Highlights
The goal of any physician who cares about dialysis patients is to increase their quality of life
Exclusion criteria: 1; any acute illness that has led to hospitalization one month before or during the study. 2; a history of allergy to NAC 3; hepatic cirrhosis and/ or increased aspartate transaminase (AST) or alanine aminotransferase (ALT) 4; The use of diuretics, or any antioxidants such as previous treatment with NAC, vitamin C or vitamin E, two weeks before or during the study 5; congestive heart failure with ejection fraction (EF)
Dialysis is the common cause of end-stage renal disease (ESRD) was main treatment method for ESRD patients, it is not diabetes mellitus (DM)
Summary
The goal of any physician who cares about dialysis patients is to increase their quality of life. Many studies have shown that residual renal function (RRF) in dialysis patients, especially those undergoing peritoneal dialysis (PD), is an important prognostic factor for mortality. In the last two decades, numerous studies have been conducted to achieve this goal These studies have shown that residual renal function (RRF) in dialysis patients, especially those undergoing peritoneal dialysis (PD), is an important prognostic factor for mortality [1,2]. Reduction of RRF leads to an increase in inflammation and reduces the clearance of uremic toxins, erythropoietin production, and fluid withdrawal These effects cause anemia, malnutrition, cardiac hypertrophy, heart failure, and atherosclerosis and vascular as well as valvular calcification which may increase cardiovascular mortality and decrease the quality of life [5]. Modalities that have already been proven to better preserve RRF include 1) Using newer dialysis membranes that are high-flux biocompatible [12]. 2) Using NAC as an antioxidant in HD and PD patients [7,13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
